The Impact of Ursodeoxycholic Acid and Probiotics on Metabolic Outcomes in Type 2 Diabetic Patients Taking Metformin

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Type 2 Diabetes Mellitus
Interventions
OTHER

Metformin Monotherapy

Participants in this group (n = 30) received metformin alone, administered in a daily dose of 1000 to 2000 mg divided into two doses, over a period of four weeks.

OTHER

Metformin combined with probiotic (Normia® Jadran Galenski Laboratory) supplementation

Participants (n = 30) received metformin (1000-2000 mg/day, divided in two doses) combined with a probiotic supplement (1 capsule three times daily) over a four-week period.

OTHER

Triple therapy - metformin, probiotic and ursodeoxycholic acid (Bilexin®, Bosnalijek)

Participants in this group (n = 30) were treated with a combination of metformin (1000 - 2000 mg/day), a probiotic (1 capsule three times daily) and ursodeoxycholic acid (UDCA, 1 capsule (250mg) three times daily) for four weeks.

Trial Locations (1)

78000

Public Health Institution Dom zdravlja Banja Luka, Banja Luka

All Listed Sponsors
lead

University of Banja Luka

OTHER